|
4. Commitments and Contingencies (Details Narrative) (USD $)
|
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Mar. 31, 2012
|
|
| Commitments And Contingencies Details Narrative | |||||
| Potential Severance of Key Executives | $ 1,918,000 | $ 1,918,000 | |||
| Aggregated Annual Salaries of Key Executives | 1,360,000 | 1,360,000 | |||
| Option payment received from AmDerma, recorded as deferred revenue | 500,000 | 500,000 | |||
| Capitalized agreement transaction costs related to More Pharma transaction | 214,000 | ||||
| Revenues from Vetericyn & Microcyn sales | 1,229,000 | 1,176,000 | 2,365,000 | 1,739,000 | |
| Outstanding receivables related to Innovacyn, Inc. | $ 375,000 | $ 375,000 | $ 290,000 | ||
| X | ||||||||||
|
- Definition
Aggregated annual salaries of key executives No definition available.
|
| X | ||||||||||
|
- Definition
Capitalized agreement transaction costs No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Option payment from AmDerma recorded as deferred revenue No definition available.
|
| X | ||||||||||
|
- Definition
Potential severance of key executives No definition available.
|
| X | ||||||||||
|
- Definition
For an unclassified balance sheet, amount of receivables arising from transactions with related parties. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|